KORU Medical Systems, Inc. (NASDAQ:KRMD – Get Free Report) CTO Eric Schiller acquired 5,000 shares of the stock in a transaction on Monday, May 18th. The shares were bought at an average price of $3.91 per share, with a total value of $19,550.00. Following the purchase, the chief technology officer directly owned 5,000 shares of the company’s stock, valued at $19,550. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
KORU Medical Systems Trading Up 3.5%
Shares of NASDAQ:KRMD opened at $4.14 on Friday. KORU Medical Systems, Inc. has a 12-month low of $2.63 and a 12-month high of $6.61. The stock has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $4.84. The stock has a market capitalization of $190.15 million, a price-to-earnings ratio of -82.80 and a beta of 0.43.
KORU Medical Systems (NASDAQ:KRMD – Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.01. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $10.90 million. As a group, equities research analysts predict that KORU Medical Systems, Inc. will post -0.04 EPS for the current year.
Institutional Trading of KORU Medical Systems
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. Wall Street Zen cut KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Tuesday, April 21st. B. Riley Financial boosted their price target on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $7.25.
Read Our Latest Stock Analysis on KORU Medical Systems
About KORU Medical Systems
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
Featured Stories
- Five stocks we like better than KORU Medical Systems
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
